Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 104 publications
Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature Search.
Journal: Dermatology and therapy
Published: May 31, 2024
Brodalumab: 4-Year US Pharmacovigilance Report.
Journal: Journal of drugs in dermatology : JDD
Published: April 07, 2023
Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry.
Journal: Journal of psoriasis and psoriatic arthritis
Published: April 01, 2023
Wolf's isotopic response of lichen planus following contact dermatitis.
Journal: JAAD case reports
Published: September 01, 2022
Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis.
Journal: Dermatology and therapy
Published: May 16, 2022
Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis.
Journal: Advances in therapy
Published: December 21, 2021
Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan® Databases.
Journal: Advances in therapy
Published: November 17, 2021
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: September 24, 2021
Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2).
Journal: Journal of drugs in dermatology : JDD
Published: August 16, 2021
Three-year U.S. pharmacovigilance report of brodalumab.
Journal: Dermatologic therapy
Published: July 27, 2021
Psoriasis treatment patterns and outcomes with ixekizumab in a real-world setting: results from a single US dermatology referral practice.
Journal: The Journal of dermatological treatment
Published: July 08, 2021
Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up.
Journal: The British journal of dermatology
Published: June 17, 2021
Last Updated: 09/26/2026